Karyopharm Therapeutics Inc.(KPTI)

Biotechnology · Newton, MA

$0.64-0.03 (-4.18%)

Delayed quote: Oct 6, 2026, 10:55 AM EDT

EBITDA Yield: N/A

Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The EBITDA yield is N/A as of 2026-10-06T14:57:33.205Z.

Stored calculation inputs

Calculation as of: 2026-10-06T14:57:33.205Z.

Quote observation: 2026-10-06T14:55:04.000Z. Amounts in USD. The price header may show a later quote.

TTM operating EBITDA · period ending 2026-06-30: N/A
Quote market capitalization: 14,560,941
Total debt · period ending 2026-06-30: 215,885,000
Cash · period ending 2026-06-30: 54,980,000

FMP input reference: 6608cd76dc650ef8b2fc8232603ca313d9f3e0951a45c9e65e7ec74b346396eb

EV/EBITDA|Earnings Yield|OCF Yield|FCF Yield|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

KPTI EBITDA Yield Metrics

EBITDA YIELD

N/A

KPTI Competitors' EBITDA Yield

KPTI

Karyopharm Therapeutics Inc.

Current

Market Cap

$14.56M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

OBX

Obsidian Therapeutics Inc.

vs KPTI

Market Cap

$14.39M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CTXR

Citius Pharmaceuticals, Inc.

vs KPTI

Market Cap

$14.01M

EBITDA Yield

N/A

TTM Avg

0.87%

3Y Avg

0.87%

5Y Avg

0.87%

KTTA

Pasithea Therapeutics Corp.

vs KPTI

Market Cap

$15.15M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

HIND

Vyome Holdings, Inc.

vs KPTI

Market Cap

$13.72M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

COCP

Cocrystal Pharma, Inc.

vs KPTI

Market Cap

$15.44M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

INAB

IN8bio, Inc.

vs KPTI

Market Cap

$13.62M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ALLR

Allarity Therapeutics, Inc.

vs KPTI

Market Cap

$15.91M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

OPTH

Optimi Health Corp.

vs KPTI

Market Cap

$13.25M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CTSO

Cytosorbents Corporation

vs KPTI

Market Cap

$13.10M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Karyopharm Therapeutics Inc. (KPTI)	$14.56M	N/A	N/A	N/A	N/A
Obsidian Therapeutics Inc. (OBX)vs ›	$14.39M	N/A	N/A	N/A	N/A
Citius Pharmaceuticals, Inc. (CTXR)vs ›	$14.01M	N/A	0.87%	0.87%	0.87%
Pasithea Therapeutics Corp. (KTTA)vs ›	$15.15M	N/A	N/A	N/A	N/A
Vyome Holdings, Inc. (HIND)vs ›	$13.72M	N/A	N/A	N/A	N/A
Cocrystal Pharma, Inc. (COCP)vs ›	$15.44M	N/A	N/A	N/A	N/A
IN8bio, Inc. (INAB)vs ›	$13.62M	N/A	N/A	N/A	N/A
Allarity Therapeutics, Inc. (ALLR)vs ›	$15.91M	N/A	N/A	N/A	N/A
Optimi Health Corp. (OPTH)vs ›	$13.25M	N/A	N/A	N/A	N/A
Cytosorbents Corporation (CTSO)vs ›	$13.10M	N/A	N/A	N/A	N/A

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

About Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.

Newton, MA

228 employees

www.karyopharm.com

Healthcare / Biotechnology